Successful Strategies for Treatment Teams to Achieve a Therapeutic Alliance and Improve Patient Outcomes in the Community Mental Health Setting

An exclusive online offer available to clinicians that have not participated in the CD-ROM version of this program.

Earn Credit* in 2 Easy Steps!

		Step 1. Click here to watch the Flash presentation.
		Step 2. Click here to take the post-test

Syllabus: If you would like to view/print a PDF of the program syllabus, Click here. If you need the Acrobat Reader, you may download it free of charge from:

http://www.adobe.com/products/acrobat/readstep2.html

* In order to be considered for credit, all post-test and evaluation forms must be received by Optima prior to September 30, 2004.

* An exclusive online offer available to clinicians that have not participated in the CD-ROM version of this program.

* Refer to the accreditation information section below for specific details on the different credit types that may be awarded.

CE: Earn 1.0 Complimentary CME Credit when you participate.

Program Description: The CMHC treatment team plays a vital role in determining the goals and objectives appropriate during acute phases of treatment, as well as during long-term management of serious and persistent mental illness. The role of the treatment team in determining these priorities and guiding the selection of suitable pharmacological and behavioral treatment strategies is critical to a successful intervention and attainment of the established goals and objectives. Within this setting, the therapeutic alliance plays a critical role in optimizing patient care and establishing compliance. This program will address practical issues in the treatment and management of schizophrenia, giving emphasis to what treatment teams can do to manage persistent symptoms, reduce the risk of relapse, and optimize health and wellness so affected individuals can work toward achieving personal life goals.

Intended Audience: Primary care physicians, psychiatrists, physician assistants, nurse practitioners, registered nurses, consultant pharmacists, pharmacists, psychologists, social workers, and case managers.

Learning Objectives: Upon completion of this activity, the participants should be able to:

• Cite pharmacologic strategies for long-term management and relapse prevention.
• Discuss recent data related to maintenance of response.
• Identify psychosocial strategies and educational resources that can be used to increase adherence and reduce relapse.

Program Chairs:

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, Irvine College of Medicine and Optima Educational Solutions, Inc. The University of California, Irvine College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement:

The University of California, Irvine College of Medicine designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Physician Assistants/Nurse Practitioners:

Physician assistants and nurse practitioners should contact their licensing agencies for verification of the AMA PRA category 1 credit equivalency shown on the certificate of participation for this course.

Nurses:

Contact hours for registered nurses are provided by the University of California as approved by the California Board of Registered Nursing, provider number 11349, for up to 1.0 contact hour. RNs outside California must verify with their licensing agency for approval of this course.

Pharmacists:

Purdue University is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. This is a continuing education activity of Purdue, an equal access/equal opportunity university. To receive the 1.0 contact hour of continuing education credit, pharmacists should complete the activity requirements and evaluation at the conclusion of the program.

ACPE# 018-999-03-071-H01
Initial release date: 10-1-03
Expiration for credit: 9-30-04

Psychologists:

Psychologists should contact their licensing agencies to determine if the AMA PRA category 1 credit shown on the certificate of participation for this course can be used for equivalent credit.

Social Workers/Case Managers:

This program was approved by the National Association of Social Workers (provider #886406659) for 1 continuing education contact hour.

Faculty Disclosures:

The presenting faculty reported the following:

Jay D. Fawver, MD is a member of the Speakers Bureaus and Advisory Boards for Eli Lilly and Company, Pfizer Inc., and Wyeth-Ayerst Pharmaceuticals.

Patricia L. Scheifler, MSW, PIP is a consultant for Eli Lilly and Company, and Pfizer Inc. She also is a member of the Advisory Boards for AstraZeneca Pharmaceuticals, and Eli Lilly and Company, and the AstraZeneca Pharmaceuticals Speakers Bureau.

The faculty discloses that they will not discuss the off-label use of any medications.

Neither Optima Educational Solutions, Inc., Eli Lilly and Company, nor their respective employees are responsible for any speaker's presentation, statement, materials, opinions, acts, or omissions.

Supported by an educational grant from Eli Lilly and Company.